AURA Biosciences (NASDAQ: AURA) insider transactions
In the twelve months to 10 November 2026, executives and directors of AURA Biosciences reported 11 open-market sales of 7,087,617 shares ($39.9m) and 0 open-market purchases, by 7 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 1 September 2026 | Person Julie | Chief People Officer | Grant or award | +107,611 | — | 107,611 | Form 4 |
| 1 September 2026 | Hopkins Janet Jill | Chief Medical Officer | Grant or award | +58,850 | — | 380,190 | Form 4 |
| 1 September 2026 | Elazzouzi Amy | SVP, Finance & PAO | Grant or award | +23,540 | — | 143,600 | Form 4 |
| 1 September 2026 | Abu-Absi Susan | Chief Operating Officer | Grant or award | +134,513 | — | 134,513 | Form 4 |
| 1 September 2026 | Kratz Erica | Chief Reg. & Quality Officer | Grant or award | +100,885 | — | 100,885 | Form 4 |
| 7 July 2026 | Bender Jeremy | Director | Grant or award | +30,000 | — | 30,000 | Form 4 |
| 1 July 2026 | Kilroy Conor | See Remarks | Grant or award | +14,858 | — | 232,693 | Form 4 |
| 16 June 2026 | Gibney Anthony S | See Remarks | Open-market sale | −12,824 | $6.42 | 265,354 | Form 4 |
| 11 June 2026 | Mattessich Antony C. | Director | Grant or award | +15,000 | — | 38,500 | Form 4 |
| 11 June 2026 | Johnson David Michael | Director | Grant or award | +15,000 | — | 194,167 | Form 4 |
| 11 June 2026 | Srivastava Sapna | Director | Grant or award | +15,000 | — | 38,500 | Form 4 |
| 11 June 2026 | Bitetti Teresa Marie | Director | Grant or award | +15,000 | — | 36,000 | Form 4 |
| 19 May 2026 | Holles Natalie C. | See Remarks | Grant or award | +600,118 | — | 600,118 | Form 4 |
| 19 May 2026 | Holles Natalie C. | See Remarks | Grant or award | +553,844 | — | 1,153,962 | Form 4 |
| 7 May 2026 | Matrix Capital Management Company, LP | — | Open-market sale | −6,922,870 | $5.64 | 0 | Form 4 |
| 16 April 2026 | Kilroy Conor | See Remarks | Open-market sale | −11,738 | $7.02 | 217,835 | Form 4 |
| 2 March 2026 | Elazzouzi Amy | Senior Vice President, Finance | Grant or award | +44,528 | — | 120,060 | Form 4 |
| 2 March 2026 | Hopkins Janet Jill | Chief Medical Officer | Grant or award | +89,056 | — | 321,340 | Form 4 |
| 2 March 2026 | Plavsic Mark | Chief Technology Officer | Grant or award | +62,339 | — | 243,736 | Form 4 |
| 2 March 2026 | de los Pinos Elisabet | See Remarks | Grant or award | +166,000 | — | 575,815 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the AURA Biosciences page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.